Drug
E7 Tcr T Cells
E7 Tcr T Cells: highest development phase Phase 2, developed by Iovance Biotherapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| E7 TCR-T cells NCT05686226 | Phase 2 | Cervical Cancer |
| E7 TCR-T cells NCT05639972 | Phase 1/2 | HPV-Associated Cervical Carcinoma |
Latest
No recent events.
Follow E7 Tcr T Cells on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.